Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ZAI Lab Begins Trial of Novel Respiratory Disease Drug

publication date: Mar 16, 2015
ZAI Lab of Shanghai has dosed the first subject in a Phase 1 study of ZL-2102, a novel anti-inflammatory drug, as a treatment for chronic respiratory diseases. The trial is being conducted in Australia among healthy volunteers. ZAI Lab in-licensed global rights to two novel compounds from Sanofi last year, both of which are potential treatments for respiratory diseases (see story). At the time, the drugs had already completed their pre-clinical development. ZL-2102 is the first to begin a clinical trial. More details....

Stock Symbol: (NYSE: SNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital